BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30022044)

  • 1. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis.
    Anwar T; Arellano-Garcia C; Ropa J; Chen YC; Kim HS; Yoon E; Grigsby S; Basrur V; Nesvizhskii AI; Muntean A; Gonzalez ME; Kidwell KM; Nikolovska-Coleska Z; Kleer CG
    Nat Commun; 2018 Jul; 9(1):2801. PubMed ID: 30022044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
    Moore HM; Gonzalez ME; Toy KA; Cimino-Mathews A; Argani P; Kleer CG
    Breast Cancer Res Treat; 2013 Apr; 138(3):741-52. PubMed ID: 23539298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
    Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
    BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
    Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression.
    Gonzalez ME; Naimo GD; Anwar T; Paolì A; Tekula SR; Kim S; Medhora N; Leflein SA; Itkin J; Trievel R; Kidwell KM; Chen YC; Mauro L; Yoon E; Andò S; Kleer CG
    iScience; 2022 Aug; 25(8):104827. PubMed ID: 35992062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.
    Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
    Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer.
    Chang PH; Chen MC; Tsai YP; Tan GYT; Hsu PH; Jeng YM; Tsai YF; Yang MH; Hwang-Verslues WW
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
    Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
    Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 14. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
    Anwar T; Gonzalez ME; Kleer CG
    Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
    Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
    Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The noncanonical role of EZH2 in cancer.
    Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
    Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
    McMullen ER; Skala SL; Gonzalez ME; Djomehri S; Chandrashekar DS; Varambally S; Kleer CG
    Breast Cancer; 2021 Mar; 28(2):496-505. PubMed ID: 33247371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 is a negative modulator of the PRC2 complex.
    Wang L; Zeng X; Chen S; Ding L; Zhong J; Zhao JC; Wang L; Sarver A; Koller A; Zhi J; Ma Y; Yu J; Chen J; Huang H
    EMBO J; 2013 May; 32(11):1584-97. PubMed ID: 23624935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.